Careside
This article was originally published in The Gray Sheet
Executive Summary
Receives FDA market go-ahead for its Careside PT prothrombin time test to measure clot formation in citrated plasma. The test would be run on the Careside analyzer, slated for launch in the U.S. during the fourth quarter, which can provide chemistry, electrochemistry and coagulation test results. The device will be priced at just under $10,000